featured
First-Line Avelumab for Cisplatin-Ineligible PD-L1–Positive Metastatic or Locally Advanced Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
Ann. Oncol 2022 Aug 01;[EPub Ahead of Print], RR Iacovelli, C Ciccarese, M Brunelli, N Battelli, C Buttigliero, C Caserta, S Buti, D Santini, C Carella, L Galli, E Verri, P Ermacora, S Merler, C Masini, R De Vivo, L Milesi, F Spina, M Rizzo, I Sperduti, G Fornarini, G TortoraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.